Catalyst calendar

Biotech catalysts in February 2027

4 catalysts are dated to February 2027, including 3 FDA decisions. The first with a set day is the FDA decision on Infigratinib (BridgeBio Pharma) on Feb 4. Events placed only in a quarter or half-year are on the 90-day calendar.

Firm dates · a specific day set by the company or regulator

Later

Feb 4
in 114 days
Infigratinib · FDA decision · Achondroplasia
BridgeBio Pharma (BBIO)·Source
Feb 12
in 122 days
Tinlarebant · FDA decision · Stargardt disease (STGD1)
Belite Bio (BLTE)·Source
Feb 27
in 137 days
Zipalertinib · FDA decision · EGFR ex20ins NSCLC · relapsed
Cullinan Therapeutics (CGEM)·Source

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in February 2027

February 2027
YUTREPIA · Phase 2a topline results (RE-WARM) · Raynaud's phenomenon associated with systemic sclerosis (SSc-RP)
Liquidia (LQDA)·Source